Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation

Abstract

The molecular basis that the viral oncoproteins, including HPV16 E6 and E1B55k/E4 34k complex, differentially target p53 but not its homolog p73 for degradation remains elusive. Using a series of p53/p73 chimeras, we demonstrated that despite binding to the different regions of p53, both HPV16 E6 and E1B55k/E4 34k required a very same p53 sequence, amino acid residues 92 to 112 [p53(aa.92–112)], previously identified as a necessity for Mdm2-mediated degradation, to target p53 for degradation. Removal of the p53(aa.92–112) by either substitution or deletion resulted in a p53 protein that was no longer degradable by the viral proteins. More significantly, swapping the oncoprotein-binding motif and the p53(aa.92–112) rendered p73 susceptible to oncoprotein-mediated degradation. Collectively, our data supports a model in which the p53(aa.92–112) functions as a determinant for p53 stability while the binding of the oncoproteins directs p53 into the specific pathway for proteolysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR . 1995 Curr. Biol. 5: 931–936

  • Balint E, Bates S, Vousden KH . 1999 Oncogene 18: 3923–3929

  • Crook T, Ludwig RL, Marston NJ, Willkomm D, Vousden KH . 1996 Virology 217: 285–292

  • Dobbelstein M, Wienzek S, Konig C, Roth J . 1999 Oncogene 18: 2101–2106

  • Dobbelstein M, Roth J . 1998 J. Gen. Virol. 79: 3079–3083

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A . 1992 Nature 356: 215–221

  • Donehower LA . 1996 Semin. Cancer Biol. 7: 269–278

  • Gu JJ, Chen DL, Rosenblum J, Rubin R, Yuan ZM . 2000 Mol. Cell. Biol. 20: 1243–1253

  • Haupt YR, Maya M, Kazaz A, Oren M . 1997 Nature 387: 296–299

  • Huibregtse J, Scheffner M, Howley P . 1991 EMBO J. 10: 4129–4135

  • Jost C, Martin M, Kaelin WG . 1997 Nature 389: 191–194

  • Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Llias J-M, Damont X, Ferrara P, McKeon F, Caput D . 1997 Cell 90: 809–819

  • Kao CC, Yew PR, Berk AJ . 1990 Virology 179: 806–814

  • Kubbutat MHG, Jones SN, Vousden KH . 1997 Nature 387: 299–303

  • Levine AJ . 1997 Cell 88: 323–329

  • Li X, Coffino P . 1996a J. Biol. Chem. 27: 4447–4451

  • Li X, Coffino P . 1996b J. Virol. 70: 4509–4516

  • Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG . 1998 Mol. Cell Biol. 18: 6316–6324

  • Marston NJ, Jenkins JR, Vousden KH . 1995 Oncogene 10: 1709–1725

  • Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS . 1998 Int. J. Oncol. 13: 5–9

  • Querido E, Marcellus RC, Lai A, Charbonneau R, Teodoro JG, Ketner G, Branton PE . 1997 J. Virol. 71: 3788–3798

  • Roth J, Konig C, Wienzek S, Weigel S, Ristea S, Dobbelstein M . 1998 J. Virol. 72: 8510–8516

  • Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM . 1990 Cell 63: 1129–1136

  • Scheffner M, Huibregtse J, Vierstra R, Howley PM . 1993 Cell 75: 495–505

  • Steegenga WT, Shvarts A, Riteco N, Bos JL, Jochemsen AG . 1999 Mol. Cell Biol. 19: 3885–3894

  • Yew PR, Berk AJ . 1992 Nature 357: 82–85

  • Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin Jr WG, Oren M, Chen J, Lu H . 1999 Mol. Cell Biol. 19: 3257–3266

Download references

Acknowledgements

This work was supported by the startup fund from the Harvard School of Public Health. We would like to thank Drs P Howley, Y Shi, P Leder, JB Little, C Maki (Harvard University) and T Shenk (Princeton University) for providing reagents.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gu, J., Rubin, R. & Yuan, ZM. A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. Oncogene 20, 3519–3527 (2001). https://doi.org/10.1038/sj.onc.1204454

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204454

Keywords

This article is cited by

Search

Quick links